DUSP22 and peripheral T-cell lymphoma, not otherwise specified: Recent advancements in molecular diagnostics, such as testing for DUSP22 and TP63 rearrangements, could offer valuable insights into ALK-negative ALCL prognosis and aid in distinguishing it from peripheral T-cell lymphoma (PTCL) NOS (5, 15).